GPATCH11

Across TCGA pan-cancer cohorts, GPATCH11 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated GPATCH11 data layer compared with 24 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher GPATCH11 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated GPATCH11 expression acts as an unfavorable survival marker, although some lineages such as LSCC and PDAC show a favorable association.

HNSC, LSCC, and PDAC are the cancer types where GPATCH11 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Quartile	III,IV	0.637	0.916	.015	17	view →
LSCC	DFS	Median	II,III,IV	0.820	0.563	.011	9	view →
PDAC	OS	Median	IV	0.951	0.381	.006	6	view →
GBM	DFS	Tertile	All	0.457	0.261	.015	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

GPATCH11–HNSC (DFS)

Open the HNSC breakdown →